Hillevax Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Hillevax Inc (HLVX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Hillevax Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Hillevax Inc | - | - | - | No |
| Competitors combined (29) | ||||
| High-Confidence Competitors (21) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
HLVX Stock Performance relative to its Competitors
HLVX Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Immunitybio inc | 282.9% | Outperformed |
| 3 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 4 | Vir Biotechnology Inc | 282.9% | Outperformed |
| 5 | Alector Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Hillevax Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Hillevax Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Hillevax Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Hillevax Inc |
104.74 | - |
 Merck and Co Inc |
362,966.50 | 66,569.00 |
 Pfizer Inc |
165,801.33 | 63,625.00 |
 Sanofi |
118,785.15 | 49,307.90 |
 Gsk Plc |
104,242.44 | 43,093.89 |
 Moderna Inc |
92,077.30 | 2,228.00 |
| SUBTOTAL | 895,107.21 | 230,127.55 |
Sign in to see all competitors of Hillevax Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Hillevax Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Hillevax Inc's Competitors Named by the Company
Competitive relationships identified from Hillevax Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Instil Bio Inc | Company report | 85% |
| Prime Medicine, Inc. | Company report | 85% |
| Moderna, Inc. | Company report | 85% |
| Capstan Therapeutics Inc. | Company report | 85% |
| Orna Therapeutics, Inc. | Company report | 85% |
| Chongqing Zhifei Biological | Company report | 85% |
| nemvaleukin | Company report | 85% |
| Arrowhead Pharmaceuticals, Inc. | Company report | 85% |
| Hoffmann La Roche Ltd. | Company report | 85% |
| Monte Rosa Therapeutics, Inc. | Company report | 85% |
| Wave Life Sciences Ltd. | Company report | 85% |
| bevacizumab | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Kymera Therapeutics, Inc. | Company report | 85% |
| Icon Genetics | Company report | 85% |
| PARP | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| Nurix Therapeutics, Inc. | Company report | 85% |
| China National Biotec | Company report | 85% |
| Cohort 4 of ARTISTRY-6 | Company report | 85% |
| argenx SE | Company report | 85% |
| Vaxart | Company report | 85% |
| pembrolizumab | Company report | 85% |
| Alnylam Pharmaceuticals, Inc. | Company report | 85% |
| Janssen | Company report | 85% |
| Beam Therapeutics Inc. | Company report | 85% |
| iECURE, Inc. | Company report | 85% |
| Tessera Therapeutics, Inc. | Company report | 85% |
| Sonnet | Company report | 85% |
| Intellia Therapeutics, Inc. | Company report | 85% |
| AstraZeneca | Company report | 85% |
| CRISPR Therapeutics AG | Company report | 85% |
| Editas Medicine, Inc. | Company report | 85% |
| Q32 Bio Inc | Company report | 85% |
| Werewolf Therapeutics Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Bnb Plus Corp | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Regenxbio Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Sangamo Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Hillevax Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Hillevax Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Immunitybio inc | Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
| Vir Biotechnology Inc | Reportable -100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Hillevax Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Hillevax Inc | 105 | - | -3,231,682 |
| Merck and Co Inc | 362,967 | 887,587 | 42,267 |
| Pfizer Inc | 165,801 | 848,333 | 54,160 |
| Sanofi | 118,785 | 21,607,316 | 3,889,794 |
| Gsk Plc | 104,242 | 169,660,977 | 32,662,867 |
| Moderna Inc | 92,077 | 474,043 | -670,426 |
| PEERS TOTAL | 895,002 | 1,356,500 | 101,061 |
Hillevax Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Merck and Co Inc | EMEA 21.50 % |
| Pfizer Inc | United States 63.93 % |
| Immunitybio inc | United States 99.79 % |
| Iovance Biotherapeutics inc | US 98.66 % |
| Novavax inc | United States 68.88 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Hillevax Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 157 companies in Hillevax Inc's industry classification, broader than the peer set above. Market cap in millions of $.Hillevax Inc ranks #0 of 157 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,443, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 254,081 | 27.22 % |
| 2 | Gilead Sciences Inc | 208,762 | 22.37 % |
| 3 | Moderna Inc | 92,077 | 9.86 % |
| 4 | Argenx Se | 64,796 | 6.94 % |
| 5 | Biogen Inc | 1,234 | 5.2% |
| 6 | Revolution Medicines Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Kymera Therapeutics Inc | 1,234 | 5.2% |
| 0 | Hillevax Inc | 105 | 0.00 % |
Market cap and industry share for the rest of Hillevax Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-09-16.
Hillevax Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.7x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 0.6x | 5.1x | -4.6x |
| Return on Equity | -44.61 % | industry aggregate | -54.35 % |
| Return on Invested Capital | -22.66 % | -11.27 % (avg) | -11.39 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Hillevax Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | -17.75 % | -23.82 % | -36.93 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Hillevax Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,443 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Hillevax Inc's dedicated Suppliers and Customers pages, not here.
Hillevax Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 54.4 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- A meaningful share of competitors (55.20 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-46.0% annualized).
Methodology: see Methodology: SWOT Analysis.
Hillevax Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Hillevax Inc | 8.48 | 16.37 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Sanofi | 0.27 | 1.09 | 0.20 |
| Gsk Plc | 0.16 | 0.82 | 0.87 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Hillevax Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Hillevax Inc | Q2 2025 | - | - |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Sanofi | Q4 2025 | +10.9 % | +46.0 % |
| Gsk Plc | Q4 2025 | +7.5 % | +120.0 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| PEERS TOTAL | +7.7 % | +6.1 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Hillevax Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Hillevax Inc | Q2 2025 | - | - |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Sanofi | Q4 2025 | +9.3 % | - |
| Gsk Plc | Q4 2025 | +7.2 % | -0.6 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
Hillevax Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Hillevax Inc | - | - | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Sanofi | 5.96% | 8.19% | 10.55% |
| Gsk Plc | 10.09% | 44.94% | 38.67% |
| Moderna Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Hillevax Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Hillevax Inc | - | - |
| Merck and Co Inc | 118.51 | 5.45 |
| Pfizer Inc | 41.03 | 2.61 |
| Sanofi | 13.45 | 2.41 |
| Gsk Plc | 13.83 | 2.42 |
| Moderna Inc | - | 41.33 |
| PEERS AVERAGE | 52.43 | 3.89 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.